Suppliers and packagers for generic pharmaceutical drug: MELOXICAM

MELOXICAM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lupin Ltd	MELOXICAM	meloxicam	CAPSULE;ORAL	209487	ANDA	Lupin Pharmaceuticals, Inc.	68180-188-06	30 CAPSULE in 1 BOTTLE (68180-188-06)	2020-12-22
Lupin Ltd	MELOXICAM	meloxicam	CAPSULE;ORAL	209487	ANDA	Lupin Pharmaceuticals, Inc.	68180-189-06	30 CAPSULE in 1 BOTTLE (68180-189-06)	2020-12-22
Novitium Pharma	MELOXICAM	meloxicam	CAPSULE;ORAL	211398	ANDA	ANI Pharmaceuticals, Inc.	70954-076-10	30 CAPSULE in 1 BOTTLE (70954-076-10)	2021-03-10
Novitium Pharma	MELOXICAM	meloxicam	CAPSULE;ORAL	211398	ANDA	ANI Pharmaceuticals, Inc.	70954-076-20	90 CAPSULE in 1 BOTTLE (70954-076-20)	2021-03-10
Novitium Pharma	MELOXICAM	meloxicam	CAPSULE;ORAL	211398	ANDA	ANI Pharmaceuticals, Inc.	70954-077-10	30 CAPSULE in 1 BOTTLE (70954-077-10)	2021-03-10
Novitium Pharma	MELOXICAM	meloxicam	CAPSULE;ORAL	211398	ANDA	ANI Pharmaceuticals, Inc.	70954-077-20	90 CAPSULE in 1 BOTTLE (70954-077-20)	2021-03-10

Meloxicam Drug: Supplier Landscape and Patent Overview

Last updated: February 19, 2026

This report analyzes the global supplier landscape for the nonsteroidal anti-inflammatory drug (NSAID) meloxicam and its associated patent expirations. Key active pharmaceutical ingredient (API) manufacturers and their geographical distribution are identified, alongside a review of significant patent protection periods relevant to the drug's lifecycle.

Who Are the Primary Manufacturers of Meloxicam API?

The production of meloxicam API is concentrated among a select group of pharmaceutical ingredient manufacturers, primarily located in Asia. These suppliers are critical to the global supply chain for both branded and generic meloxicam formulations.

Manufacturer Name	Primary Location	Key Product Focus	Notes
Boehringer Ingelheim	Germany	Branded Meloxicam (Mobic®)	Original patent holder and marketer of the branded product.
Dr. Reddy's Laboratories	India	Generic Meloxicam API	Significant global supplier of generic APIs.
Aurobindo Pharma	India	Generic Meloxicam API	Another major Indian API producer with substantial global reach.
Sun Pharmaceutical Industries	India	Generic Meloxicam API	A large Indian pharmaceutical company with a broad API portfolio.
Cadila Healthcare (Zydus Cadila)	India	Generic Meloxicam API	Active in API manufacturing and finished dosage forms.
Cipla	India	Generic Meloxicam API	A long-standing Indian pharmaceutical company with a global presence.
Teva Pharmaceutical Industries	Israel	Generic Meloxicam API	One of the world's largest generic drug manufacturers.
Sanofi	France	Branded & Generic Formulations	While historically a major player, focuses more on finished products.
Novagen Pharma	India	Generic Meloxicam API	An emerging player in the API market.
IOL Chemicals and Pharmaceuticals	India	Generic Meloxicam API	Specializes in bulk drug manufacturing.

These manufacturers adhere to stringent Good Manufacturing Practices (GMP) to ensure product quality and regulatory compliance for global markets, including the United States, Europe, and other key regions. Supply agreements with finished dosage form manufacturers are critical for market access and price competitiveness.

What is the Patent Expiration Timeline for Meloxicam?

The patent landscape for meloxicam is largely characterized by the expiration of its primary composition of matter patents. The drug's core patent protection has elapsed, paving the way for widespread generic competition.

• Original Composition of Matter Patent: Filed by Boehringer Ingelheim, the foundational patents covering the meloxicam molecule itself have long expired. The initial U.S. patent was granted in the early 1990s, with a 20-year lifespan from the filing date.
• Exclusivity Periods: Following patent expiration, the drug experienced periods of market exclusivity granted by regulatory bodies, such as the U.S. Food and Drug Administration (FDA). For instance, new chemical entity (NCE) exclusivity typically lasts five years in the U.S.
• Patent Litigation and Extensions: As with many pharmaceuticals, there have been instances of patent litigation related to method-of-use patents or formulation patents. In some cases, patent term extensions (PTEs) can be granted to compensate for regulatory review delays, potentially extending market exclusivity. However, the core patents for meloxicam have expired.
• Generic Entry: The expiration of key patents and subsequent loss of exclusivity has led to the significant entry of generic meloxicam products into the market, driving down prices and increasing accessibility.

The primary patent protection for meloxicam has expired, with the composition of matter patent having lapsed decades ago. This has allowed generic manufacturers to enter the market freely, provided they meet regulatory requirements for quality and bioequivalence.

What Are the Key Regulatory Considerations for Meloxicam API Suppliers?

Suppliers of meloxicam API must navigate a complex web of international regulatory requirements to ensure market access and product compliance.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the FDA, the European Medicines Agency (EMA), and other national health authorities. This includes rigorous quality control, process validation, and documentation.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review the API information without disclosing proprietary data to the drug product manufacturer.
• ANDA Submissions: Finished dosage form manufacturers rely on the API supplier's DMF when submitting an Abbreviated New Drug Application (ANDA) for generic meloxicam. The FDA reviews the DMF as part of the ANDA approval process.
• Import Alerts and Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities, both domestically and internationally. Suppliers may be subject to import alerts if deficiencies are found, potentially disrupting supply chains.
• Pharmacopeial Standards: Meloxicam API must meet the specifications outlined in recognized pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
• Impurity Profiling: Stringent requirements exist for controlling and reporting impurities in APIs. Manufacturers must demonstrate that their processes effectively manage known and potential impurities to levels deemed safe by regulatory authorities.

Compliance with these regulations is non-negotiable for API suppliers seeking to serve regulated markets.

What Are the Major Global Markets for Meloxicam?

The demand for meloxicam is substantial across developed and emerging economies, driven by its efficacy in treating osteoarthritis, rheumatoid arthritis, and other inflammatory conditions.

• United States: This is a significant market for meloxicam, with a large patient population and a well-established generic drug market. The FDA's rigorous approval process ensures high standards for both API and finished product.
• European Union: The EU represents another major market, with individual member states having their own regulatory pathways and prescribing patterns. The EMA oversees drug approvals across the bloc.
• Japan: The Japanese market is characterized by high-quality standards and a demand for innovative and generic pharmaceutical products.
• India: As a major producer of APIs and finished generics, India is also a substantial domestic market for meloxicam, driven by its large population and healthcare access initiatives.
• China: China is a growing market for pharmaceuticals, with increasing demand for effective pain management solutions. Its role as a manufacturing hub also impacts global supply.
• Other Key Markets: This includes countries in South America, Southeast Asia, the Middle East, and Africa, where access to affordable NSAIDs is a growing priority.

Market penetration is influenced by healthcare infrastructure, reimbursement policies, physician prescribing habits, and the competitive pricing of generic alternatives.

What are the Key Challenges and Opportunities for Meloxicam Suppliers?

The meloxicam market presents both inherent challenges and avenues for growth for API manufacturers.

Challenges:

• Price Pressure: The highly competitive generic market exerts significant downward pressure on API prices. Suppliers must achieve economies of scale and optimize production costs to remain profitable.
• Regulatory Scrutiny: Continuous adherence to evolving global GMP standards and regulatory requirements demands ongoing investment in quality systems and compliance.
• Supply Chain Disruptions: Geopolitical events, natural disasters, and global health crises can disrupt raw material sourcing and finished product distribution, impacting reliability.
• Impurity Control: Meeting increasingly stringent limits on process-related impurities and potential genotoxic impurities requires sophisticated analytical capabilities and process optimization.
• Intellectual Property Landscape: While core patents have expired, staying abreast of any remaining formulation or method-of-use patents that could impact market access is crucial.

Opportunities:

• Emerging Markets: Growing healthcare access and demand for affordable pain management in developing economies present significant growth opportunities.
• Contract Manufacturing: Offering contract manufacturing services to pharmaceutical companies seeking to outsource API production can be a revenue stream.
• Process Innovation: Developing more efficient, cost-effective, or environmentally sustainable manufacturing processes can provide a competitive advantage.
• Quality Leadership: Establishing a reputation for exceptional quality and reliable supply can differentiate suppliers in a crowded market.
• Vertical Integration: Companies that can integrate API production with the manufacturing of finished dosage forms may capture additional value.

Navigating these factors effectively will determine the success of meloxicam API suppliers in the global pharmaceutical market.

Key Takeaways

• Meloxicam API manufacturing is dominated by Indian and, to a lesser extent, other global suppliers.
• The primary composition of matter patents for meloxicam have expired, facilitating robust generic competition.
• Suppliers must adhere to strict global GMP and regulatory standards, evidenced by DMF submissions and facility inspections.
• Major markets include the United States, the EU, Japan, India, and China, with significant growth potential in emerging economies.
• Key challenges for suppliers include intense price pressure and continuous regulatory scrutiny, while opportunities lie in expanding into new markets and optimizing manufacturing processes.

Frequently Asked Questions

1. What is the primary reason for the intense price competition in the meloxicam API market? The expiration of foundational patents has led to a surge in generic manufacturers producing meloxicam API, creating a highly competitive supply environment where price is a critical factor for market share.

2. How do regulatory agencies like the FDA and EMA ensure the quality of meloxicam API from international suppliers? These agencies utilize a combination of reviewing Drug Master Files (DMFs), conducting on-site inspections of manufacturing facilities, and setting pharmacopeial standards that APIs must meet.

3. Beyond core API production, what other intellectual property considerations might impact meloxicam suppliers or their customers? While the molecule patent is expired, there could be patents related to specific polymorphic forms, novel formulations, or methods of use (e.g., new indications or delivery systems) that could influence market exclusivity for certain finished products.

4. What impact does the concentration of API manufacturing in specific geographic regions have on global supply chain resilience? A high concentration in regions like India can create vulnerabilities. Disruptions in these areas, whether due to geopolitical factors, natural disasters, or local regulatory actions, can have a significant impact on global availability and pricing of meloxicam.

5. Are there specific impurity profiles that regulatory bodies are particularly vigilant about for meloxicam API? Regulatory bodies are generally vigilant about controlling any process-related impurities, including residual solvents, heavy metals, and any potentially genotoxic impurities. Manufacturers must demonstrate consistent control over these to acceptable limits.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files-dmfs [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-advice-formalities/good-manufacturing-practice [3] United States Pharmacopeia. (n.d.). About USP. Retrieved from https://www.usp.org/about-usp [4] Boehringer Ingelheim. (n.d.). Our history. Retrieved from https://www.boehringer-ingelheim.com/corporate-profile/our-history